A compound of Formula I,

##STR00001##

is disclosed. In Formula I, M is Pd or Pt; each of X.sup.1 to X.sup.12 is C or N; each of X.sup.13 and X.sup.14 is CH, CD or N; each of Z.sup.1, Z.sup.2, and Z.sup.3 is C or N; L.sup.1 is selected from a variety of bivalent linkers; X is selected from O, S, Se, NR′, and CR″R′″; each R, R′, R.sup.1, R.sup.2, R.sup.3, R.sup.A, R.sup.B, R.sup.C, R.sup.D, and R.sup.E is hydrogen or a General Substituent; at least one of Z.sup.1, Z.sup.2, and Z.sup.3 is a carbon atom substituted with a substituent with a molecular weight of at least 16. Formulations, OLEDs, and consumer products that include Formula I are also disclosed.

A compound of Formula I,

##STR00001##

is disclosed. In Formula I, M is Pd or Pt; each of X.sup.1 to X.sup.12 is C or N; each of X.sup.13 and X.sup.14 is CH, CD or N; each of Z.sup.1, Z.sup.2, and Z.sup.3 is C or N; L.sup.1 is selected from a variety of bivalent linkers; X is selected from O, S, Se, NR′, and CR″R′″; each R, R′, R.sup.1, R.sup.2, R.sup.3, R.sup.A, R.sup.B, R.sup.C, R.sup.D, and R.sup.E is hydrogen or a General Substituent; at least one of Z.sup.1, Z.sup.2, and Z.sup.3 is a carbon atom substituted with a substituent with a molecular weight of at least 16. Formulations, OLEDs, and consumer products that include Formula I are also disclosed.

The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. For example, HPCs of NSAIA have demonstrated indications such as treating hair loss and bold. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The invention provides compositions or pharmaceutical compositions of novel high penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. For example, HPCs of NSAIA have demonstrated indications such as treating hair loss and bold. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

The present invention relates to a composition comprising a compound of formula (H1) and a compound of formula (H2). The present invention furthermore relates to a formulation comprising a composition comprising a compound of formula (H1) and a formula (H2) and a solvent. Finally, the present invention relates to an electronic device comprising a such a composition.

The present invention relates to a composition comprising a compound of formula (H1) and a compound of formula (H2). The present invention furthermore relates to a formulation comprising a composition comprising a compound of formula (H1) and a formula (H2) and a solvent. Finally, the present invention relates to an electronic device comprising a such a composition.

Provided are a family of chromophores including naphthyl or naphthyl-like carbocyclic or heterocyclic rings as luminescent dyes that can be useful as emitters in OLEDs. These compounds have Formula I,

##STR00001##

Also provided are formulations including these inventive compounds. Further provided are OLEDs and related consumer products that utilize these inventive compounds.

Provided are a family of chromophores including naphthyl or naphthyl-like carbocyclic or heterocyclic rings as luminescent dyes that can be useful as emitters in OLEDs. These compounds have Formula I,

##STR00001##

Also provided are formulations including these inventive compounds. Further provided are OLEDs and related consumer products that utilize these inventive compounds.

High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the conditions that the parent drugs or parent drug-related compounds can. Additionally, the HPCs are capable of reaching areas that their parent drugs or parent drug-related compounds may not be able to access or to render a sufficient concentration at the target areas HPCs of NSAIA, for example, have demonstrated indications such as treating hair loss. A HPC can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.